Here are the needs by age: 0 to 6 months - 40 mg 7 to 12 months - 50 mg 1 to 3 years - 15 mg 4 to 8 years - 25 mg 9 to 13 years 45 mg 14 to 18 years - 75 mg for males and 65 mg for females 19 + years - 90 mg for males and 75 mg for females (Source 2, 3) These needs represent the recommended dietary allowances (RDAs), although you can safely take higher dosages with supplements
If you are a carnivore, eat adrenal glands and pituitary
Reported side effects (minimal) Common experience: Very well-tolerated (most users report zero sides) Decades of Russian use without serious issues Dipeptide (just 2 amino acids) = low immunogenicity Occasional mild effects: Injection site reactions : Redness, slight swelling (normal) Mild headache first 1-2 days (rare) Fatigue or drowsiness (uncommon) No major side effects reported What Cartalax does NOT cause: No GI upset (unlike NSAIDs ) No systemic effects (tissue-specific) No hormonal disruption No dependency or withdrawal Generally very safe Long-term safety: Russian use 30+ years No serious adverse events documented Cyclic use pattern reduces continuous exposure Bioregulator approach inherently safer Well-established safety profile Contraindications: Pregnancy / breastfeeding (not studied) Active cancer (theoretical growth factor concern) Severe immune dysfunction (unknown effects) Otherwise: Generally safe Monitoring recommendations Before starting: Baseline joint function assessment Note pain levels, mobility, stiffness Take progress photos if visible swelling Document current medications Blood work (optional, for comprehensive baseline) During cycles: Track daily subjective joint feelings Note any side effects Pain scale tracking (1-10) Mobility changes Overall quality of life After cycles: Reassess joint function monthly Compare to baseline Determine cycle frequency needed Adjust protocol based on response Patient long-term approach When to discontinue: Any severe reactions (extremely rare) No benefit after 2-3 cycles Unacceptable side effects Medical concerns arise Alternative treatment preferred See peptide safety and risks comprehensive guide
According to randomized, double-blind, crossover clinical studies, Calocurb increases the bodys GLP-1 production by up to 600%, participants consumed 18% fewer calories, reported a 30% reduction in hunger and 40% reduction in cravings
